Novartis AG (NVS)

Revenue Breakdown

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013	Dec 31, 2012
Innovative Medicines Revenue	55.38B	54.53B	50.32B
Revenue (Other)	1.99B	2.14B	1.41B
Revenue (Total)	57.36B	56.67B	51.72B

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013	Dec 31, 2012
United States Revenue (Post-Q2 2023 Reporting)	22.68B	23.33B	21.15B
Europe Revenue (Post-Q2 2023 Reporting)	17.33B	16.73B	15.56B
Asia/Africa/Australasia Revenue (Post-Q2 2023 Reporting)	11.52B	10.80B	10.02B
Canada and Latin America Revenue (Post-Q2 2023 Reporting)	3.85B	3.68B	3.59B
Revenue (Other)	1.99B	2.14B	1.41B
Revenue (Total)	57.36B	56.67B	51.72B

Revenue Breakdown 2

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013	Dec 31, 2012
Cardiovascular, Renal And Metabolic Revenue	6.76B	8.96B	8.58B
Immunology Revenue	10.85B	10.29B	9.29B
Neuroscience Revenue	7.04B	5.99B	4.75B
Oncology Revenue	17.47B	16.83B	14.30B
Established Brands Revenue	13.26B	12.46B	13.40B
Revenue (Total)	57.36B	56.67B	51.72B

Key Performance Indicators

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013	Dec 31, 2012
Cosentyx Revenue	7.05B	6.67B	6.14B
Gilenya Revenue	-	-	552.00M
Entresto Revenue	4.90B	7.75B	7.82B
Tasigna Revenue	617.00M	1.10B	1.67B
Lucentis Revenue	450.00M	643.00M	1.04B

Data Source: Fiscal.ai Last updated: Oct 27, 2026

Financial data is provided by Fiscal.ai and updates within minutes after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Nov 13, 2026

Data Sources Report a data error